CA9 and neoplasm: Severe adverse events attributable to off-tumor effects were also reported in clinical trials involving patients with metastatic solid tumors: evidence of hepatotoxicity was observed in a clinical study evaluating carbonic anhydrase-IX (CAIX).CAR-T cells for the treatment of metastatic renal cell carcinoma.